Compare iShares MSCI France ETF (EWQ) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI France ETF vs BIO-TECHNE Corp — how do they compare? iShares MSCI France ETF trades at $41.36 (market cap $334.71M), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: BIO-TECHNE Corp is far larger — about 34× iShares MSCI France ETF's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while iShares MSCI France ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI France ETF for 55 Days and BIO-TECHNE Corp for 63 Days on average.
| EWQ | TECH | |
|---|---|---|
Market Cap | $334.71M | $11.37B |
Volume | 897,168 | 3,153,511 |
Sector | Broad Market / Factor | Health |
52-Week High | $48.35 | $72.61 |
52-Week Low | $41.32 | $43.31 |
Typical Hold Time | 55 Days | 63 Days |
Enterprise Value | — | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWQ is currently trading at $41.34, down 1.12% on the day, with technical indicators showing a bearish trend despite oversold RSI readings. The stock faces significant technical pressure with moving averages signaling strong selling momentum. Recent news highlights European market volatility driven by ECB rate hikes and energy price inflation, creating headwinds for European-focused investments.
The outlook remains cautious as monetary tightening and geopolitical risks weigh on European equities. Key support sits at $41 with resistance at $42, while oversold conditions suggest potential for near-term stabilization. However, sustained recovery depends on easing inflation pressures and improved eurozone economic sentiment.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI France ETF
EWQ is a country-specific ETF that tracks the performance of the French equity market. It provides exposure to major global brands across sectors like luxury goods, industrials, and healthcare, including LVMH, Schneider Electric, and Hermes.
Read more on EWQ →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
